Sign in
4

Changes in Ownership

Alkermes plc. Filed Acc 0001127602-24-028885

EVP R&D, Chief Medical Officer sold 61,151 shares at $32.07 ($1,961,406)

  • EVP R&D, Chief Medical Officer acquired 48,997 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2024-12-09 Option exercise 10b5-1 +12,452 $20.03 $249,414 72,182 D
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2024-12-09 Option exercise 10b5-1 +12,090 $19.34 $233,821 84,272 D
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2024-12-09 Option exercise 10b5-1 +12,044 $24.59 $296,162 96,316 D
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2024-12-09 Option exercise 10b5-1 +12,411 $26.82 $332,863 108,727 D
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2024-12-09 Sale 10b5-1 −61,151 $32.07 $1,961,406 47,576 D
Derivatives
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2024-12-09 Option exercise · Employee Stock Option (Right to Buy) 10b5-1 −12,452 116,722 D
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2024-12-09 Option exercise · Employee Stock Option (Right to Buy) 10b5-1 −12,090 188,323 D
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2024-12-09 Option exercise · Employee Stock Option (Right to Buy) 10b5-1 −12,044 130,300 D
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2024-12-09 Option exercise · Employee Stock Option (Right to Buy) 10b5-1 −12,411 110,616 D
Open-market sales · 61,151 sh · avg $32.07 · $1,961,406
Loading xslF345X05/form4.xml…